MT-101 – AKI, CKD
An antibody candidate designed to normalize vascular function and protect kidney function through Tie2 activation
MT-101 as a Tie2-activating mAb for treating renal diseases (AKI, CKD)
Modality
Monoclonal antibody
Mechanism of Action
Direct Tie2 activation and inhibition of Ang-2 binding to Tie2 to stabilize the vascular endothelium and normalize vascular function
Indications
Acute kidney injury (AKI), chronic kidney disease (CKD)
Development Status
Preclinical studies ongoing
Key Differentiators
Demonstrated the highest Tie2 activation and endothelial cell survival activity among the antibodies tested, together with strong inhibition of Ang-2 binding to Tie2
(Preclinical comparisons used antibodies produced in-house based on publicly disclosed competitor patents.)A differentiated approach targeting structural and functional vascular normalization through direct Tie2 activationImprovement in renal vascular injury observed across multiple preclinical kidney disease modelsSelected for support under the Korea Drug Development Fund (KDDF) in 2023
Market Opportunity
Significant unmet needs remain in kidney disease settings where effective treatment options are limited, including acute kidney injury. Through vascular normalization driven by Tie2 activation, MT-101 aims to address these needs as a differentiated antibody therapy with potential applications across acute kidney injury and chronic kidney disease.
Development & Partnerships
Co-developed with MabTics
Pursuing global partnering and out-licensing opportunities